RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

about

RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?Advances in understanding prognosis in myeloma.Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma

P2860

Q28260541-22999876-B96C-401C-B410-40F4223EB725 Q30244061-AEA6BE8B-35FC-4634-9CFA-94F8D7653641 Q58756391-36A1667B-B0AB-4BA1-8FC0-3932815C5D25

P2860

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

Item

http://www.wikidata.org/entity/Q45066307

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@en

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@nl

type

Item

label

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@en

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@nl

prefLabel

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@en

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

@nl

P1476

RAS mutation status and bortezomib therapy for relapsed multiple myeloma

@en

P2093

Anna Lach

http://www.w3.org/2001/XMLSchema#string

Dean Smith

http://www.w3.org/2001/XMLSchema#string

Elena Armenteros

http://www.w3.org/2001/XMLSchema#string

Gaelle Herledan

http://www.w3.org/2001/XMLSchema#string

Kwee Yong

http://www.w3.org/2001/XMLSchema#string

Laura Percy

http://www.w3.org/2001/XMLSchema#string

Madhu Kumar

http://www.w3.org/2001/XMLSchema#string

Matthew Stubbs

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical and biological significance of RAS mutations in multiple myeloma.

Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma.

Phase II study of bortezomib-dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma

International uniform response criteria for multiple myeloma.

International Myeloma Working Group recommendations for global myeloma care.

Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.

P304

905-908

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.13258

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P50

Julian Downward

P577

2015-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25580780

http://www.w3.org/2001/XMLSchema#string

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

about

P2860

P2860

RAS mutation status and bortezomib therapy for relapsed multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698